Evidence map›Paper›PMID 38888724›Full record

ArticlePharmacological reports : PR2024

In vitro biological evaluation of a novel folic acid-targeted receptor quantum dot-β-cyclodextrin carrier for C-2028 unsymmetrical bisacridine in the treatment of human lung and prostate cancers.

Joanna Pilch, Agnieszka Potęga, Patrycja Kowalik, Agata Kowalczyk, Piotr Bujak, Artur Kasprzak, Ewa Paluszkiewicz, Anna Maria Nowicka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacological reports : PR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Quantum Dot-Enabled Biosensing for Prostate Cancer Diagnostics.Nanomaterials (Basel, Switzerland) · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joanna PilchFaculty of Chemistry, Gdańsk University of Technology, Narutowicza 11/12 Str., Gdańsk, 80-233, Poland. joanna.pilch@pg.edu.pl.ORCID http://orcid.org/0000-0003-3476-2540
Agnieszka PotęgaFaculty of Chemistry, Gdańsk University of Technology, Narutowicza 11/12 Str., Gdańsk, 80-233, Poland.ORCID http://orcid.org/0000-0003-1853-9277
Patrycja KowalikInstitute of Physical Chemistry, Polish Academy of Science, Warsaw, Poland.
Agata KowalczykFaculty of Chemistry, University of Warsaw, Warsaw, Poland.ORCID http://orcid.org/0000-0002-1911-8311
Piotr BujakFaculty of Chemistry, Warsaw University of Technology, Warsaw, Poland.
Artur KasprzakFaculty of Chemistry, Warsaw University of Technology, Warsaw, Poland.ORCID http://orcid.org/0000-0002-4895-1038
Ewa PaluszkiewiczFaculty of Chemistry, Gdańsk University of Technology, Narutowicza 11/12 Str., Gdańsk, 80-233, Poland.
Anna Maria NowickaFaculty of Chemistry, University of Warsaw, Warsaw, Poland.ORCID http://orcid.org/0000-0002-5872-6010

Funding

Narodowe Centrum Nauki 2020/37/N/NZ7/01979
6 · The paper itself

Abstract

backgroundTraditional small-molecule chemotherapeutics usually do not distinguish tumors from healthy tissues. However, nanotechnology creates nanocarriers that selectively deliver drugs to their site of action. This work is the next step in the development of the quantum dot-β-cyclodextrin-folic acid (QD-β-CD-FA) platform for targeted and selected delivery of C-2028 unsymmetrical bisacridine in cancer therapy.

methodsHerein, we report an initial biological evaluation (using flow cytometry and light microscopy) as well as cell migration analysis of QD-β-CD(C-2028)-FA nanoconjugate and its components in the selected human lung and prostate cancer cells, as well as against their respective normal cells.

resultsC-2028 compound induced apoptosis, which was much stronger in cancer cells compared to normal cells. Conjugation of C-2028 with QD

conclusionsIn conclusion, the results demonstrate the high potential of a novel folic acid-targeted receptor quantum dot-β-cyclodextrin carrier (QD

Indexed as

Apoptosisbeta-CyclodextrinsDrug CarriersFolic AcidLung NeoplasmsProstatic NeoplasmsQuantum DotsAcridinesAntineoplastic AgentsCell Line, TumorCell MovementDrug Delivery SystemsHumansMaleAcridinesAntineoplastic Agentsbeta-CyclodextrinsDrug CarriersFolic AcidBiological responseDrug delivery nanosystemFolic acidTargeted cancer therapyUnsymmetrical bisacridine

Identifiers

PMID38888724
PMCPMC11294431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.